Properties (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:approves |
gptkb:FDA
2012 |
| gptkbp:availability |
prescription only
|
| gptkbp:chemicalFormula |
C22H30N4O5S
|
| gptkbp:clinicalTrials |
combination therapy
ASCO guidelines monotherapy Phase 1 trial Phase 2 trial Phase 3 trial NCCN_guidelines EHA_guidelines |
| gptkbp:contraindication |
infection risk
pulmonary toxicity cardiac toxicity hypersensitivity to carfilzomib renal toxicity severe heart problems severe liver problems |
| gptkbp:developedBy |
gptkb:Onyx_Pharmaceuticals
|
| gptkbp:drugInterdiction |
highly protein-bound
|
| gptkbp:financial_aid |
reconstituted solution for 24 hours
|
| gptkbp:formulation |
lyophilized powder
|
| https://www.w3.org/2000/01/rdf-schema#label |
Carfilzomib
|
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:lastProduced |
2012
|
| gptkbp:locatedIn |
2000s
|
| gptkbp:mandates |
refractory multiple myeloma
relapsed multiple myeloma |
| gptkbp:marketedAs |
gptkb:Canada
gptkb:USA Europe |
| gptkbp:numberOfStudents |
approximately 15 minutes
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:offers |
high
|
| gptkbp:patentExpiration |
2027
|
| gptkbp:patentStatus |
patented
|
| gptkbp:researchFocus |
long-term effects
new formulations combination regimens biomarker_identification |
| gptkbp:route |
IV
|
| gptkbp:sells |
Kyprolis
|
| gptkbp:sideEffect |
anemia
fatigue nausea diarrhea thrombocytopenia |
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
cancer cells
|
| gptkbp:triggerType |
proteasome inhibitor
|
| gptkbp:usedFor |
multiple myeloma
|
| gptkbp:variant |
dexamethasone
lenalidomide |
| gptkbp:waterManagement |
bile
|